-
ALSO READ
Sensex jumps 210 pts, Nifty ends above 16,600 led by IT, FMCG stocks
Nifty hits fresh record high; breadth remains strong
Divi's Laboratories consolidated net profit rises 16.72% in the September 2021 quarter
Nifty scales fresh record high above 16,000 mark
Divi's Laboratories consolidated net profit rises 29.31% in the March 2021 quarter
-
The domestic equity benchmarks were currently trading near the day's high in afternoon trade. The Nifty was trading above the 17,500 mark. Healthcare stocks were in demand. Rising COVID-19 cases in Europe kept investor's sentiment in check.
At 13:22 IST, the barometer index, the S&P BSE Sensex, was up 425.44 points or 0.73% to 58,766.43. The Nifty 50 index added 107.55 points or 0.62% to 17,522.60.
In the broader market, the S&P BSE Mid-Cap index rose 0.17% while the S&P BSE Small-Cap index gained 0.52%.
The market breadth was strong. On the BSE, 1935 shares rose and 1264 shares fell. A total of 140 shares were unchanged.
Economy:
A report issued by economists at HDFC Bank, which released on Wednesday, said: "India's GDP will show a 7.8% expansion on a year-on-year basis for the September 2021 quarter. Real GDP will grow 9.4% in FY22 and decelerate to 7.5% for FY23 as the base effects result in the higher growth in the ongoing fiscal wear-off."
In FY21, the GDP had contracted 7.3% due to the pandemic. For FY22, the RBI expects GDP to clock a growth of 9.5%, which will slow to 7.8% in FY23. The GDP had expanded by over 20% for the first quarter on the lower base. The official data for the second quarter is set to be released on 30 November 2021.
Buzzing Index:
The Nifty Healthcare index rose 1.13% to 8,662.80. The index declined 0.60% yesterday.
Torrent Pharmaceuticals (up 6.05%), Laurus Labs (up 4.35%), Apollo Hospitals Enterprise (up 2.62%), Glenmark Pharmaceuticals (up 2.10%), Dr. Reddy's Laboratories (up 1.58%), Aurobindo Pharma (up 1.34%), Alembic Pharmaceuticals (up 1.11%), Granules India (up 1.06%) and Divi's Laboratories (up 1.05%) advanced.
Concurrently, Ipca Laboratories (down 1.80%), Metropolis Healthcare (down 0.84%) and Pfizer (down 0.44%) declined.
Stocks in Spotlight:
Grasim Industries added 0.31% to Rs 1751.45. Life Insurance Corporation of India (LIC) sold 1,33,50,869 equity shares or 2.028% stake of Grasim Industries from 24 September 2020 to 23 November 2021. Post transaction, LIC's stake in the company has declined to 9.830% from 11.858% held earlier.
Aurionpro Solutions rose 3.07% to Rs 213.30. The company has bagged an order in the smart transit segment from the Government of Uttar Pradesh. The project is expected to be worth more than Rs 60 crore, over five years, with the minimum guaranteed revenue.
Global Markets:
Most Asian stocks were trading higher on Thursday.
The Bank of Korea raised its policy rate by 25 basis points to 1%, a move that was largely expected.
The prices Japanese companies charge each other for services rose 1.0% in October from a year earlier, their eighth straight month of gains and a sign inflationary pressure was building due to higher global commodity costs.
The services producer price index hit 105.4 in October, the highest since November 2001, Bank of Japan (BOJ) data showed on Thursday.
U.S. stocks pushed modestly higher on Wednesday as the recent jump in bond yields took a breather, allowing tech stocks to recover. The meetings from the latest Fed meeting, released on Wednesday, showed that the central bankers were ready to accelerate the timetable for slowing asset purchases and raising the benchmark funds rate if inflation remains high.
U.S. markets will be closed for the Thanksgiving holiday on Thursday. The stock market closes early on Friday.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU